Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
GlaxoSmithKline plc (GSK), a leading name in the pharmaceutical preparation manufacturing industry, is headquartered in the United Kingdom. Founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK has established itself as a key player in the global healthcare landscape, with significant operations across Europe, North America, and emerging markets.
GSK focuses on developing innovative medicines, vaccines, and consumer healthcare products, with a commitment to addressing some of the world's most pressing health challenges. Its core offerings include treatments for respiratory diseases, HIV, and vaccines that are recognised for their efficacy and safety. With a strong emphasis on research and development, GSK has achieved notable milestones, including advancements in immunology and oncology, solidifying its position as a trusted leader in the pharmaceutical sector.
+58 vs industry average
Glaxosmithkline’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing has typical carbon intensity
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
GlaxoSmithKline (GSK), a UK-headquartered pharmaceutical manufacturer, reported Scope 1 emissions of approximately 479 million kg CO2e and Scope 2 (market-based) emissions of 7 million kg CO2e in 2025. In 2024, GSK reported Scope 1 emissions of approximately 521 million kg CO2e, Scope 2 (market-based) emissions of 44 million kg CO2e, and Scope 3 emissions of approximately 8.385 billion kg CO2e. For 2023, the company disclosed Scope 1 emissions of approximately 580 million kg CO2e, Scope 2 (market-based) emissions of 64 million kg CO2e, and Scope 3 emissions of approximately 8.983 billion kg CO2e.
GSK has established robust climate commitments. The company aims for net-zero greenhouse gas emissions across its full value chain by 2045, targeting a 90% absolute reduction from a 2020 baseline across all scopes, with residual emissions neutralised through high-quality offsets. This aligns with Science Based Targets initiative (SBTi) long-term targets for Scope 1, 2, and 3 emissions, all committed to a 90% reduction by 2045 from a 2020 base year.
For near-term targets, GSK commits to an 80% absolute reduction in Scope 1 and 2 GHG emissions by 2030 from a 2020 base year. Similarly, it aims to reduce absolute Scope 3 GHG emissions from specific categories (purchased goods and services, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, use of sold products, and end-of-life treatment of sold products) by 80% within the same timeframe. These near-term targets are classified as consistent with a 1.5°C warming trajectory by the SBTi. GSK had previously committed to a 34% reduction in absolute Scope 1 and 2 GHG emissions by 2025 from a 2017 base year, and a 16% reduction in absolute Scope 3 GHG emissions by 2030 from a 2017 base year.
The company also reported a 15% reduction in Scope 1 and 2 carbon emissions in 2021 compared to 2020. GSK signed The Climate Pledge in August 2021, reinforcing its commitment to achieve net-zero carbon emissions by 2040.
2045
90% reduction in Scope 2
GSK commits to reduce absolute scope 2 GHG emissions 90% by 2045 from a 2020 base year.
2030
80% reduction in Scope 2
GSK commits to reduce absolute scope 2 GHG emissions 80% by 2030 from a 2020 base year.
2045
GSK commits to reach net-zero greenhouse gas emissions acros…
GSK commits to reach net-zero greenhouse gas emissions across the value chain by 2045 from a 2020 base year.
See all 7 climate goals
Already have an account? Sign in now
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Glaxosmithkline’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more